Home > Riviste > Minerva Cardiology and Angiology > Fascicoli precedenti > Minerva Cardiology and Angiology 2022 October;70(5) > Minerva Cardiology and Angiology 2022 October;70(5):555-62



Opzioni di pubblicazione
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca


Publication history
Per citare questo articolo



Minerva Cardiology and Angiology 2022 October;70(5):555-62

DOI: 10.23736/S2724-5683.20.05494-8


lingua: Inglese

Trend of perceived quality of life and functional capacity in outpatients with chronic heart failure and in treatment with sacubitril/valsartan: a real-life experience

Giuseppe DATTILO 1, Roberto BITTO 1, Michele CORREALE 2 , Claudia MORABITO 1, Vittoria VACCARO 1, Giulia LATERRA 1, Matteo CASALE 1, Pasquale CREA 1, Gianluca DI BELLA 1, Francesco LUZZA 1, Alessandro MIGLIORATO 1, Niki KATSIKI 3, Cesare DE GREGORIO 1

1 Section of Cardiology, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy; 2 Unit of Cardiology, Policlinico Riuniti University Hospital, Foggia, Italy; 3 School of Medicine, Second Department of Propaedeutic Internal Medicine, Hippocration Hospital, Aristotle University, Thessaloniki, Greece

BACKGROUND: Despite the use of optimal medical therapy, heart failure and reduced left ventricular ejection fraction (HFrEF) remains a leading cause of morbidity, mortality and health care costs. The introduction of angiotensin receptor/neprilysin inhibitors (ARNIs) had a revolutionary impact on the treatment of patients with HFrEF. The aim of the study was to monitor over time the perceived quality of life, the physical performance, the trend of BNP and NT-ProBNP and the NYHA functional class in patients with HFrEF during treatment with sacubitril/valsartan.
METHODS: We enrolled 37 patients (63±10 years old, 76% men) who underwent a total of one-year follow-up. All patients underwent clinical evaluation, 6MWT, blood analysis (in particular, NT-pro-BNP and BNP, renal function test); Kansas City Cardiomyopathy Questionnaire (KCCQ) and the NYHA functional class assessment were also performed, at the beginning of the study and after 3, 6 and 12 months of therapy.
RESULTS: We observed at each follow-up a significant improvement of KCCQ score, 6MWT, NT-ProBNP, BNP and NYHA class. However, analyzing the ∆% of variation of each single parameter, the improvement was not uniform in time. We also observed that only 37% of patients tolerated the full recommended dose of sacubitril/valsartan (97/103 mg b.i.d.); of the remaining, 40% tolerated the intermediate dose (49/51 mg b.i.d.) and 23% the minimum (24/26 md b.i.d.).
CONCLUSIONS: Sacubitril/valsartan therapy improves significantly quality of life, physical effort resistance, BNP and NT-ProBNP and NYHA functional class in patients with HFrEF. Although not all the patients tolerated the maximum recommended dose, the beneficial effects were significant even at lower doses.

KEY WORDS: Heart failure; Sacubitril and valsartan sodium hydrate drug combination; Natriuretic Peptides

inizio pagina